NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
Clinical Trials
33 trialsNCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
NCT03541486 2025-03-10
XACT-PANC-2
University of Iowa
Phase 2 Withdrawn
NCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT05861336 2024-12-27
OVERPASS
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Withdrawn
NCT02745197 2024-09-19
A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer
University of Alberta
Phase 2 Withdrawn
NCT06110598 2024-08-15
CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT06518538 2024-08-15
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT06398587 2024-07-19
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03245658 2023-12-18
The Effect of Cannabis in Pancreatic Cancer
University of Copenhagen
Phase 2 Withdrawn
NCT05216120 2023-07-03
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
HonorHealth Research Institute
Phase 2 Withdrawn
NCT03199144 2022-06-23
CKPancreas
Centre Francois Baclesse, Luxembourg
Phase 2 Withdrawn
NCT05212025 2022-06-14
Adavosertib and Gemcitabine in Advanced Pancreatic
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02850874 2022-04-27
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT03509298 2020-10-19
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
Phase 2 Withdrawn
NCT00226746 2020-09-18
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
New York Presbyterian Brooklyn Methodist Hospital
Phase 2 Withdrawn
NCT03038477 2020-09-14
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
University of Colorado, Denver
Phase 2 Withdrawn
NCT00882765 2020-07-31
Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04058964 2020-03-13
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00728000 2019-11-25
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Withdrawn
NCT04130399 2019-10-17
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Indiana University
Phase 2 Withdrawn
NCT01524575 2019-09-25
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
University of Hawaii
Phase 2 Withdrawn
NCT02885727 2019-09-12
Panc-Durval+RT
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT03432676 2019-05-30
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02967770 2018-09-11
PanCAN
Georgetown University
Phase 2 Withdrawn
NCT00386399 2018-07-12
Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT01045941 2016-10-06
Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT00253526 2015-04-28
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02310971 2015-04-03
Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Prima BioMed Ltd
Phase 2 Withdrawn
NCT01130701 2015-03-17
PMABIIS
University of Massachusetts, Worcester
Phase 2 Withdrawn
NCT00005591 2013-12-13
Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT00487851 2013-04-12
Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer
Karolinska Institutet
Phase 2 Withdrawn